Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial

特奈特普酶 医学 改良兰金量表 冲程(发动机) 纤溶剂 丸(消化) 麻醉 临床试验 组织纤溶酶原激活剂 溶栓 外科 内科学 缺血性中风 心肌梗塞 缺血 工程类 机械工程
作者
Andrew Bivard,Henry Zhao,Leonid Churilov,Bruce Campbell,Skye Coote,Nawaf Yassi,Bernard Yan,Michael Valente,Angelos Sharobeam,Anna Balabanski,Angela Dos Santos,Jo Lyn Ng,Vignan Yogendrakumar,Felix Ng,Francesca Langenberg,Damien Easton,Alex Warwick,Elizabeth A. Mackey,Amy MacDonald,Gagan Sharma
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:21 (6): 520-527 被引量:125
标识
DOI:10.1016/s1474-4422(22)00171-5
摘要

Background Mobile stroke units (MSUs) equipped with a CT scanner reduce time to thrombolytic treatment and improve patient outcomes. We tested the hypothesis that tenecteplase administered in an MSU would result in superior reperfusion at hospital arrival, when compared with alteplase. Methods The TASTE-A trial is a phase 2, randomised, open-label trial at the Melbourne MSU and five tertiary hospitals in Melbourne, VIC, Australia. Patients (aged ≥18 years) with ischaemic stroke who were eligible for thrombolytic treatment were randomly allocated in the MSU to receive, within 4·5 h of symptom onset, either standard-of-care alteplase (0·9 mg/kg [maximum 90 mg], administered intravenously with 10% as a bolus over 1 min and 90% as an infusion over 1 h), or the investigational product tenecteplase (0·25 mg/kg [maximum 25 mg], administered as an intravenous bolus over 10 s), before being transported to hospital for ongoing care. The primary outcome was the volume of the perfusion lesion on arrival at hospital, assessed by CT-perfusion imaging. Secondary safety outcomes were modified Rankin Scale (mRS) score of 5 or 6 at 90 days, symptomatic intracerebral haemorrhage and any haemorrhage within 36 h, and death at 90 days. Assessors were masked to treatment allocation. Analysis was by intention-to-treat. The trial was registered with ClinicalTrials.gov, NCT04071613, and is completed. Findings Between June 20, 2019, and Nov 16, 2021, 104 patients were enrolled and randomly allocated to receive either tenecteplase (n=55) or alteplase (n=49). The median age of patients was 73 years (IQR 61–83), and the median NIHSS at baseline was 8 (5–14). On arrival at the hospital, the perfusion lesion volume was significantly smaller with tenecteplase (median 12 mL [IQR 3–28]) than with alteplase (35 mL [18–76]; adjusted incidence rate ratio 0·55, 95% CI 0·37–0·81; p=0·0030). At 90 days, an mRS of 5 or 6 was reported in eight (15%) patients allocated to tenecteplase and ten (20%) patients allocated to alteplase (adjusted odds ratio [aOR] 0·70, 95% CI 0·23–2·16; p=0·54). Five (9%) patients allocated to tenecteplase and five (10%) patients allocated to alteplase died from any cause at 90 days (aOR 1·12, 95% CI 0·26–4·90; p=0·88). No cases of symptomatic intracerebral haemorrhage were reported within 36 h with either treatment. Up to day 90, 13 serious adverse events were noted: five (5%) in patients treated with tenecteplase, and eight (8%) in patients treated with alteplase. Interpretation Treatment with tenecteplase on the MSU in Melbourne resulted in a superior rate of early reperfusion compared with alteplase, and no safety concerns were noted. This trial provides evidence to support the use of tenecteplase and MSUs in an optimal model of stroke care. Funding Melbourne Academic Centre for Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
七dgdg完成签到 ,获得积分20
1秒前
1秒前
2秒前
2秒前
小黑完成签到,获得积分10
2秒前
2秒前
2秒前
Nicole完成签到 ,获得积分10
2秒前
ggdh发布了新的文献求助10
3秒前
3秒前
Hello的应助被yyyyj采纳,获得10
3秒前
yangy801017发布了新的文献求助10
3秒前
SunD发布了新的文献求助10
5秒前
5秒前
cdercder的应助被wjjoo采纳,获得10
5秒前
Ellis发布了新的文献求助10
5秒前
ding的应助被博修采纳,获得10
6秒前
xianianrui发布了新的文献求助10
6秒前
唐艺尹完成签到,获得积分10
6秒前
养只缅因发布了新的文献求助10
7秒前
某某完成签到,获得积分10
8秒前
8秒前
年轻雁枫发布了新的文献求助10
9秒前
ZS发布了新的文献求助10
9秒前
愉快的月光完成签到,获得积分20
10秒前
哈哈哈发布了新的文献求助10
10秒前
11秒前
shuyiWang发布了新的文献求助10
11秒前
12秒前
12秒前
12秒前
走走发布了新的文献求助10
12秒前
13秒前
13秒前
14秒前
14秒前
kk发布了新的文献求助10
15秒前
饺子123完成签到,获得积分20
16秒前
科科发布了新的文献求助10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168242
求助须知:如何正确求助?哪些是违规求助? 9561251
关于积分的说明 21760749
捐赠科研通 7759644
什么是DOI,文献DOI怎么找? 3429959
关于科研通互助平台的介绍 2553785
邀请新用户注册赠送积分活动 2474561